FMR LLC trimmed its stake in shares of GH Research PLC (NASDAQ:GHRS - Free Report) by 7.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,745,445 shares of the company's stock after selling 220,929 shares during the quarter. FMR LLC owned 5.28% of GH Research worth $18,367,000 at the end of the most recent quarter.
Separately, Lynx1 Capital Management LP boosted its holdings in shares of GH Research by 19.8% in the second quarter. Lynx1 Capital Management LP now owns 3,966,726 shares of the company's stock valued at $46,252,000 after acquiring an additional 656,163 shares during the period. 56.90% of the stock is owned by institutional investors.
Analyst Ratings Changes
A number of brokerages have recently commented on GHRS. Canaccord Genuity Group cut their target price on shares of GH Research from $31.00 to $28.00 and set a "buy" rating on the stock in a report on Monday, November 18th. HC Wainwright reaffirmed a "buy" rating and issued a $40.00 target price on shares of GH Research in a report on Wednesday, November 20th. Finally, JMP Securities reissued a "market outperform" rating and set a $39.00 price target on shares of GH Research in a report on Wednesday, September 4th.
Check Out Our Latest Stock Report on GH Research
GH Research Stock Performance
GHRS traded down $0.37 during trading on Wednesday, hitting $8.60. The stock had a trading volume of 88,033 shares, compared to its average volume of 78,097. The firm has a market capitalization of $447.44 million, a P/E ratio of -11.35 and a beta of 0.78. GH Research PLC has a twelve month low of $5.05 and a twelve month high of $14.99. The company's 50-day moving average price is $8.24 and its 200 day moving average price is $9.94.
GH Research Profile
(
Free Report)
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
Read More
Before you consider GH Research, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GH Research wasn't on the list.
While GH Research currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
